Filing Flows › Kymera Therapeutics (KYMR) › Q2 2026 › vs Q1 2026
Kymera Therapeutics (KYMR) Q2 2026 vs Q1 2026 (quarter over quarter)
Kymera Therapeutics's revenue rose $30.6M (+89%) from $34.4M in Q1 2026 to $65.0M in Q2 2026.
Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $65.0M | $34.4M | $30.6M | +89% |
| Other income, net | $14.4M | $14.9M | −$524K | -4% |
| Net loss | $61.2M | $69.2M | −$8.0M | -12% |
| Costs & expenses | $141M | $119M | $22.1M | +19% |
| Operating costs | $141M | $119M | $22.1M | +19% |
| Operating cash sources | $75.0M | $107M | −$31.8M | -30% |
| Depreciation & amortization | $2.0M | $2.0M | $8K | +0.4% |
| Share-based compensation | $18.9M | $16.0M | $2.9M | +18% |
| Cash used in operations | $54.1M | $88.8M | −$34.8M | -39% |
| Net loss absorbed | $61.2M | $69.2M | −$8.0M | -12% |
| Working capital & other | $13.8M | $37.6M | −$23.8M | -63% |
Questions
How much did Kymera Therapeutics's revenue grow quarter over quarter in Q2 2026?
Kymera Therapeutics's revenue rose $30.6M (+89%) from $34.4M in Q1 2026 to $65.0M in Q2 2026.